These include sarcoidosis, high phosphate blood levels, high calcium blood levels, excessive vitamin D levels, arteriosclerosis with occlusion of the arteries, kidney stones, kidney disease with reduced kidney function, and allergies to vitamin D
Based on the available research, CJC-1295 may be appropriate for: Adults with symptoms consistent with age-related GH decline (confirmed by IGF-1 testing) Patients interested in evidence-based peptide therapy with established pharmacokinetic data Individuals who want GH improvement through a physiologic, pituitary-stimulating approach rather than exogenous GH Those willing to work with a physician who monitors their response through lab work Frequently Asked Questions Is CJC-1295 supported by clinical evidence
This does not affect our editorial coverage or your price
Most of our patients get a significant reduction in symptoms within 6-8 months
This is particularly beneficial for patients who experience severe side effects with standard dosing, as it allows them to continue treatment without compromising their comfort or safety
A Titan Krios equipped with a Gatan K3 Summit direct electron detector and serial EM3.7 were used to acquire cryo-EM images